Leerink Partnrs Forecasts Beigene’s Q1 Earnings (NASDAQ:ONC)

Beigene, Ltd. (NASDAQ:ONC) – Stock analysts at Leerink Partnrs cut their Q1 2025 earnings estimates for shares of Beigene in a research note issued to investors on Monday, April 28th. Leerink Partnrs analyst A. Berens now expects that the company will earn ($0.61) per share for the quarter, down from their prior forecast of ($0.51). The consensus estimate for Beigene’s current full-year earnings is ($5.82) per share. Leerink Partnrs also issued estimates for Beigene’s Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.49 EPS, FY2025 earnings at ($0.23) EPS and FY2027 earnings at $14.00 EPS.

Beigene (NASDAQ:ONC) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.55). The company had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.09 billion. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%.

Several other analysts have also recently weighed in on ONC. JMP Securities set a $348.00 price objective on Beigene in a research report on Friday, February 28th. Guggenheim reaffirmed a “buy” rating on shares of Beigene in a research report on Wednesday, April 16th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $312.00 price objective on shares of Beigene in a research report on Monday. Bank of America raised Beigene from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $207.00 to $320.00 in a research report on Monday, March 3rd. Finally, JPMorgan Chase & Co. lifted their price objective on Beigene from $311.00 to $317.00 and gave the company an “overweight” rating in a research report on Monday, April 21st. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Beigene currently has a consensus rating of “Buy” and an average target price of $318.88.

Beigene Price Performance

NASDAQ ONC opened at $255.64 on Thursday. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $25.29 billion, a PE ratio of -31.02, a PEG ratio of 7.73 and a beta of 0.49. Beigene has a 1 year low of $141.31 and a 1 year high of $287.88. The business has a 50-day simple moving average of $248.24.

Insider Activity

In related news, COO Xiaobin Wu sold 51,921 shares of the business’s stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $281.40, for a total value of $14,610,569.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bros. Advisors Lp Baker sold 732,827 shares of the business’s stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $260.00, for a total transaction of $190,535,020.00. Following the completion of the transaction, the director now owns 730,642 shares of the company’s stock, valued at approximately $189,966,920. The trade was a 50.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,146,048 shares of company stock worth $295,198,300. Insiders own 6.62% of the company’s stock.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.